Please provide your email address to receive an email when new articles are posted on . Mineralocorticoid receptor antagonists disrupt the renin-angiotensin-aldosterone system and provide beneficial ...
Steroidal MRAs particularly benefit patients on dialysis, whereas nonsteroidal MRAs help treat patients with nondialysis-dependent CKD. Steroidal mineralocorticoid receptor antagonists (MRAs) reduce ...
Credit: Italfarmaco. The approval was based on data from the randomized, double-blind, placebo-controlled phase 3 EPIDYS study. Duvyzat is the first nonsteroidal treatment approved for patients with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback